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Beneficial effects of clopidogrel combined with aspirin in reducing
cerebral emboli in patients undergoing carotid endarterectomy
Payne DA, Jones CI, Hayes PD, et al. Circulation 2004;109:1476-81.
Conclusion: The combination of clopidogrel and aspirin reduces
emboli detected by transcranial Doppler ultrasound after carotid endarter-
ectomy (CEA), but results in an increased time to achieve hemostasis
following flow restoration.
Summary: One hundred patients on routine aspirin therapy (150 mg)
undergoing CEA were randomized the night prior to surgery to placebo (n
5 4), or 75 mg of clopidogrel (n  46). Platelet reactivity was assessed by
response to adenosine 5 phosphate (ADP). Emboli detected by transcranial
Doppler ultrasound within the first 3 hours of CEA were quantified. The
time from flow restoration to skin closure was used as a measure of the time
to secure hemostasis.
In comparison to placebo, clopidogrel produced an 8.8% reduction in
platelet response to ADP (P  .05) and conferred a tenfold reduction in
relative risk of having 20 emboli in the postoperative period (odds ratio,
10.23; 95% confidence interval, 1.3-83.3; P  .01). Time from flow resto-
ration to skin closure was significantly increased in the clopidogrel-treated
patients (P  .04). There were no increases in postoperative bleeding
complications or blood transfusions. There were no deaths, and 1 patient in
each group suffered a stroke.
Comment: The data allow one to conclude that use of clopidogrel as a
perioperative antiplatelet agent will increase time to hemostasis following
restoration of flow during CEA. The data do not indicate that a reduction in
postoperative embolization detected by transcranial Doppler ultrasound
translates into a reduction in clinical stroke. To determine whether periop-
erative use of clopidogrel would result in a decrease in stroke following CEA
would require a very large, and perhaps not feasible, randomized trial. To
determine that clopidogrel results in an increase in pesky bleeding following
CEA requires only operating on a few patients receiving clopidogrel in
conjunction with their CEA.
Variable ventilation improves perioperative lung function in patients
undergoing abdominal aortic aneurysmectomy
Boker A, Aberman CJ, Girling L, et al. Anesthesiology 2004;100:608-16.
Conclusion: In patients undergoing abdominal aortic aneurysm
(AAA) repair, variable ventilation (VV) delivering variable respiratory rates
and title volumes results in improved lung function over continuous venti-
lation delivering consistent title volumes at fixed rates.
Summary: Patients undergoing AAA repair frequently have perioper-
ative deterioration of lung function. In this study the authors sought to
determine whether VV was superior to control mode ventilation (CV) in
patients undergoing AAA repair. Forty-one patients were included in the
study. While under general anesthesia with conventional ventilation using a
title volume of 10 mm/kg and respiratory rate of 10 breathes per minute,
patients were randomized to either continue CV or were switched to VV. In
patients undergoing VV, there was computer control of the ventilator with
the same overall ventilation as for patients undergoing CV but with 376
different combinations of respiratory rate and title volume. Lung function
was assessed through measurements of dead space ventilation, alveolar to
arterial oxygen difference, areas under pressure time expiatory flow curves,
and peak expiatory pressures.
Patients randomized to CV and those randomized to VV were similar
with regard to age, weight, body mass index, preoperative pulmonary
function testing, smoking history, and ASA status. Patients with VV had
greater arterial oxygen partial pressure (P  .011), lower arterial carbon
dioxide partial pressure (P .012), lower dead space ventilation (P .011),
increased compliance (P  .049), and lower mean peak expiatory pressure
(P .013). Examination of chest x-rays revealed no differences in severity of
atelectasis between the 2 groups.
Comment: Normal ventilation is characterized by variability. In fact,
most, if not all, physiologic parameters manifest some variability. Other data
suggest that variability of physiologic function is associated with health and
that loss of variability may indicate deterioration (Am J Crit Care Med
2001;163:1289-96). The authors’ findings are therefore compatible with
the old adage “variety is the spice of life.”
Effects of cholesterol-lowering with simvastatin on stroke and other
major vascular events in 20,536 people with cerebrovascular disease or
other high-risk conditions
Heart Protection Study Collaborative Group. Lancet 2004;363:757-67.
Conclusion: With no increase in rates of cerebral hemorrhage, statin
therapy reduces the incidence of coronary events and ischemic strokes even
among individuals who do not have high cholesterol concentrations.
Summary: The study addressed the fact that lower blood cholesterol
concentrations are consistently associated with lower risk of coronary disease
but not always with a lower risk of stroke. This large-scale, prospective study
addressed the impact of statin therapy on stroke and other major vascular
events. The authors randomly allocated 40 mg of simvastatin daily or
placebo to 3,280 adults with cerebrovascular disease and an additional
17,256 adults with occlusive arterial disease or diabetes. Prespecified end-
points included “major vascular events” (eg, nonfatal myocardial infarction,
coronary death, stroke of any type, or any revascularization procedure). An
intention-to-treat analysis was used, and during the 5- year treatment period
there was an average difference in low-density lipoprotein cholesterol of 39
mg/dL between the simvastatin- and placebo-treated groups.
There was a highly significant 25% (95% confidence interval, 15%-34%)
reduction in the first-event rate for stroke for patients using simvastatin
(4.3%) versus placebo (5.7%; P  .0001) reflecting a 28% (19%-37%)
reduction in presumed ischemic strokes (P  .0001) and no apparent
difference in strokes attributed to hemorrhage (hazard ratio 0.95, 0.65-1.4);
P  .8). Stroke reduction was not significant during the first year but
obtained significance by the end of the second year (P  .0004). Among
patients with preexisting cerebrovascular disease, there was no apparent
reduction in the stroke rate, but there was a highly significant 20% (8-29)
reduction in the rate of any major vascular event (P  .001). Proportional
reductions in stroke were about 25% in each of the subcategories of partic-
ipants in the study. These included those with coronary disease or diabetes,
those aged under or over 70 years at entry, and those who presented with
different levels of blood pressure or lipids even when the pretreatment
low-density lipoprotein cholesterol was 116mg/dL.
Comment: There has been debate regarding the ability of cholesterol-
lowering medications to favorably influence stroke rates. This study now
provides definitive evidence that statin therapy is beneficial for people with
cerebrovascular disease and results in reduction of stroke in all categories of
patients with extracranial arterial disease.
Short telomeres are associated with increased carotid atherosclerosis in
hypertensive subjects
Benetos A, Gardner JP, Zureik M, et al. Hypertension 2004;43:182-5.
Conclusion: Short telomere length in white blood cells (WBCs) is
associated with an increased predilection to carotid artery atherosclerosis.
Summary: It is thought that telomere length in WBCs may be a marker
of the cumulative burden of oxidative stress and inflammation during an
individual’s lifetime. Telomere length, therefore, may help explain inter-
individual variation in carotid disease associated with aging and hyperten-
sion. The authors sought to examine the relationship between telomere
length, as expressed in WBCs, to the presence of carotid artery plaques in
males with hypertension.
Data were obtained from 163 men under treatment for hypertension
who volunteered for a screening medical examination. Extracranial carotid
plaques were assessed with B-mode ultrasound. Telomere length was mea-
sured from DNA extracted from WBCs.
Telomere length was shorter in hypertensive men with carotid artery
plaques than in hypertensive men without plaques (8.17  0.07 kilobase
[kb] vs 8.46 0.07 kb; P .01). Multivariable analysis indicated that both
age and telomere length were independent predictors of the presence of
carotid artery plaque.
Comment: The authors have attempted to answer at least partially the
question as to why some hypertensive patients are more prone to developing
atherosclerotic lesions than others. There is a complex relationship between
telomere length, oxidative stress, and antioxidant capacity. Overall, the data
indicate telomere length may be an indicator of cardiovascular risk and aging
of the vasculature in humans.
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